Victory Capital Management
SYRS

Victory Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Victory Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-779
Closed -$46K – 3361
2020
Q1 		$46K Buy
+779
New +$52.8K ﹤0.01% 2814
2019
Q4 		– Sell
-481
Closed -$50K – 3350
2019
Q3 		$50K Buy
+481
New +$45.4K ﹤0.01% 2685

Other funds holding SYRS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management's SYRS Position: Q2 2020 in Review

Victory Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2020, closing a stake of 779 shares — an estimated $46K sold.

Victory Capital Management first reported a position in SYRS in Q3 2019 and held it in 2 quarters. The position peaked at $50K in Q3 2019. 79 funds tracked by Wall St. Rank hold SYRS as of Q2 2020.

  • Victory Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 779 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $46K.
  • Victory Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.